Skip to main content

Table 3 Adjusted Cox hazards regression models for specific opportunistic illnesses for patients who used combination antiretroviral therapy (N = 1878 individuals)

From: Predictors of opportunistic illnesses incidence in post combination antiretroviral therapy era in an urban cohort from Rio de Janeiro, Brazil

 

Tuberculosis

Esophageal candidiasis

Cerebral Toxoplamosis

PCP

 

(N = 30)

(N = 10)

(N = 12)

(N = 8)

 

HR (CI)

HR (CI)

HR (CI)

HR (CI)

Gender-Risk

    

 Women

Ref.

Ref.

Ref.

Ref.

 Heterosexual men

0.85 (0.38–1.88)

0.15 (0.02–1.25)

1.46 (0.39–5.43)

0.81 (0.16–4.20)

 MSM

0.53 (1.89–1.58)

0.25 (0.05–1.42)

0.31 (0.05–2.00)

0.59 (0.08–4.16)

Age (per year)

1.02 (0.99–1.06)

0.93 (0.86–1.02)

0.91 (0.84–0.99)

1.07 (1.00–1.14)

Race/ethnicity

    

 White

Ref.

Ref.

Ref.

Ref.

 Non-white

0.86 (0.39–1.88)

2.10 (0.43–10.29)

0.46 (0.14–1.51)

1.26 (0.27–5.87)

Educational level

    

 0–8 years

2.08 (0.78–5.51)

0.89 (0.19–4.12)

1.22 (0.29–5.10)

0.38 (0.07–2.03)

 9+ years

Ref.

Ref.

Ref.

Ref.

Nadir CD4+ T lymphocyte (per 100 cells/mm3)

0.85 (0.63–1.15)

0.73 (0.42–1.25)

0.89 (0.59–1.33)

1.25 (0.83–1.90)

Opportunistic illness at enrollment

23.0 (9.60–55.2)

13.6 (2.93–63.3)

34.6 (8.50–141.4)

21.5 (2.86–162.1)

Time under cART (per year)

0.78 (0.63–0.97)

0.55 (0.29–1.03)

0.61 (0.39–0.96)

0.60 (0.33–1.08)

  1. PCP Pneumocystis jiroveci pneumonia, HR hazard ratio, CI 95 % confidence interval, MSM men who have sex with men
  2. Bold font implies statistically significant results assuming a 5 % significance threshold